MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 17, 2017, MYOS RENS Technology Inc. (the “Company”) received a received a written letter of resignation from Zhengguang Lyu stating that he resigned, effective immediately, from his position as a director of the Company.
About MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS)
MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement. MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) Recent Trading Information
MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) closed its last trading session down -0.11 at 2.84 with 98,708 shares trading hands.
